TGFB1 Single Nucleotide Polymorphisms Are Associated With Adverse Quality of Life in Prostate Cancer Patients Treated With Radiotherapy

Christopher A. Peters, Richard G. Stock, Jamie A. Cesaretti, David P. Atencio, Sheila Peters, Ryan J. Burri, Nelson N. Stone, Harry Ostrer, Barry S. Rosenstein

Research output: Contribution to journalArticle

50 Citations (Scopus)

Abstract

Purpose: To investigate whether the presence of single nucleotide polymorphisms (SNPs) located within TGFB1 might be predictive for the development of adverse quality-of-life outcomes in prostate cancer patients treated with radiotherapy. Methods and Materials: A total of 141 prostate cancer patients treated with radiotherapy were screened for SNPs in TGFB1 using DNA sequencing. Three quality-of-life outcomes were investigated: (1) prospective decline in erectile function, (2) urinary quality of life, and (3) rectal bleeding. Median follow-up was 51.3 months (range, 12-138 months; SD, 24.4 months). Results: Those patients who possessed either the T/T genotype at position -509, the C/C genotype at position 869 (pro/pro, codon 10) or the G/C genotype at position 915 (arg/pro, codon 25) were significantly associated with the development of a decline in erectile function compared with those who did not have these genotypes: 56% (9 of 16) vs. 24% (11 of 45) (p = 0.02). In addition, patients with the -509 T/T genotype had a significantly increased risk of developing late rectal bleeding compared with those who had either the C/T or C/C genotype at this position: 55% (6 of 11) vs. 26% (34 of 130) (p = 0.05). Conclusions: Possession of certain TGFB1 genotypes is associated with the development of both erectile dysfunction and late rectal bleeding in patients treated with radiotherapy for prostate cancer. Therefore, identification of patients harboring these genotypes may represent a means to predict which men are most likely to suffer from poor quality-of-life outcomes after radiotherapy for prostate cancer.

Original languageEnglish (US)
Pages (from-to)752-759
Number of pages8
JournalInternational Journal of Radiation Oncology Biology Physics
Volume70
Issue number3
DOIs
StatePublished - Mar 1 2008
Externally publishedYes

Fingerprint

polymorphism
nucleotides
Single Nucleotide Polymorphism
radiation therapy
Prostatic Neoplasms
Radiotherapy
cancer
Genotype
Quality of Life
bleeding
Hemorrhage
Codon
sequencing
Erectile Dysfunction
deoxyribonucleic acid
DNA Sequence Analysis

Keywords

  • Prostate cancer
  • Radiogenomics
  • Radiotherapy
  • Single nucleotide polymorphisms (SNPs)
  • Transforming growth factor β1 (TGF-β1)

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

TGFB1 Single Nucleotide Polymorphisms Are Associated With Adverse Quality of Life in Prostate Cancer Patients Treated With Radiotherapy. / Peters, Christopher A.; Stock, Richard G.; Cesaretti, Jamie A.; Atencio, David P.; Peters, Sheila; Burri, Ryan J.; Stone, Nelson N.; Ostrer, Harry; Rosenstein, Barry S.

In: International Journal of Radiation Oncology Biology Physics, Vol. 70, No. 3, 01.03.2008, p. 752-759.

Research output: Contribution to journalArticle

Peters, Christopher A. ; Stock, Richard G. ; Cesaretti, Jamie A. ; Atencio, David P. ; Peters, Sheila ; Burri, Ryan J. ; Stone, Nelson N. ; Ostrer, Harry ; Rosenstein, Barry S. / TGFB1 Single Nucleotide Polymorphisms Are Associated With Adverse Quality of Life in Prostate Cancer Patients Treated With Radiotherapy. In: International Journal of Radiation Oncology Biology Physics. 2008 ; Vol. 70, No. 3. pp. 752-759.
@article{72ebc167f1894569bd018992e30bfc8b,
title = "TGFB1 Single Nucleotide Polymorphisms Are Associated With Adverse Quality of Life in Prostate Cancer Patients Treated With Radiotherapy",
abstract = "Purpose: To investigate whether the presence of single nucleotide polymorphisms (SNPs) located within TGFB1 might be predictive for the development of adverse quality-of-life outcomes in prostate cancer patients treated with radiotherapy. Methods and Materials: A total of 141 prostate cancer patients treated with radiotherapy were screened for SNPs in TGFB1 using DNA sequencing. Three quality-of-life outcomes were investigated: (1) prospective decline in erectile function, (2) urinary quality of life, and (3) rectal bleeding. Median follow-up was 51.3 months (range, 12-138 months; SD, 24.4 months). Results: Those patients who possessed either the T/T genotype at position -509, the C/C genotype at position 869 (pro/pro, codon 10) or the G/C genotype at position 915 (arg/pro, codon 25) were significantly associated with the development of a decline in erectile function compared with those who did not have these genotypes: 56{\%} (9 of 16) vs. 24{\%} (11 of 45) (p = 0.02). In addition, patients with the -509 T/T genotype had a significantly increased risk of developing late rectal bleeding compared with those who had either the C/T or C/C genotype at this position: 55{\%} (6 of 11) vs. 26{\%} (34 of 130) (p = 0.05). Conclusions: Possession of certain TGFB1 genotypes is associated with the development of both erectile dysfunction and late rectal bleeding in patients treated with radiotherapy for prostate cancer. Therefore, identification of patients harboring these genotypes may represent a means to predict which men are most likely to suffer from poor quality-of-life outcomes after radiotherapy for prostate cancer.",
keywords = "Prostate cancer, Radiogenomics, Radiotherapy, Single nucleotide polymorphisms (SNPs), Transforming growth factor β1 (TGF-β1)",
author = "Peters, {Christopher A.} and Stock, {Richard G.} and Cesaretti, {Jamie A.} and Atencio, {David P.} and Sheila Peters and Burri, {Ryan J.} and Stone, {Nelson N.} and Harry Ostrer and Rosenstein, {Barry S.}",
year = "2008",
month = "3",
day = "1",
doi = "10.1016/j.ijrobp.2007.05.023",
language = "English (US)",
volume = "70",
pages = "752--759",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - TGFB1 Single Nucleotide Polymorphisms Are Associated With Adverse Quality of Life in Prostate Cancer Patients Treated With Radiotherapy

AU - Peters, Christopher A.

AU - Stock, Richard G.

AU - Cesaretti, Jamie A.

AU - Atencio, David P.

AU - Peters, Sheila

AU - Burri, Ryan J.

AU - Stone, Nelson N.

AU - Ostrer, Harry

AU - Rosenstein, Barry S.

PY - 2008/3/1

Y1 - 2008/3/1

N2 - Purpose: To investigate whether the presence of single nucleotide polymorphisms (SNPs) located within TGFB1 might be predictive for the development of adverse quality-of-life outcomes in prostate cancer patients treated with radiotherapy. Methods and Materials: A total of 141 prostate cancer patients treated with radiotherapy were screened for SNPs in TGFB1 using DNA sequencing. Three quality-of-life outcomes were investigated: (1) prospective decline in erectile function, (2) urinary quality of life, and (3) rectal bleeding. Median follow-up was 51.3 months (range, 12-138 months; SD, 24.4 months). Results: Those patients who possessed either the T/T genotype at position -509, the C/C genotype at position 869 (pro/pro, codon 10) or the G/C genotype at position 915 (arg/pro, codon 25) were significantly associated with the development of a decline in erectile function compared with those who did not have these genotypes: 56% (9 of 16) vs. 24% (11 of 45) (p = 0.02). In addition, patients with the -509 T/T genotype had a significantly increased risk of developing late rectal bleeding compared with those who had either the C/T or C/C genotype at this position: 55% (6 of 11) vs. 26% (34 of 130) (p = 0.05). Conclusions: Possession of certain TGFB1 genotypes is associated with the development of both erectile dysfunction and late rectal bleeding in patients treated with radiotherapy for prostate cancer. Therefore, identification of patients harboring these genotypes may represent a means to predict which men are most likely to suffer from poor quality-of-life outcomes after radiotherapy for prostate cancer.

AB - Purpose: To investigate whether the presence of single nucleotide polymorphisms (SNPs) located within TGFB1 might be predictive for the development of adverse quality-of-life outcomes in prostate cancer patients treated with radiotherapy. Methods and Materials: A total of 141 prostate cancer patients treated with radiotherapy were screened for SNPs in TGFB1 using DNA sequencing. Three quality-of-life outcomes were investigated: (1) prospective decline in erectile function, (2) urinary quality of life, and (3) rectal bleeding. Median follow-up was 51.3 months (range, 12-138 months; SD, 24.4 months). Results: Those patients who possessed either the T/T genotype at position -509, the C/C genotype at position 869 (pro/pro, codon 10) or the G/C genotype at position 915 (arg/pro, codon 25) were significantly associated with the development of a decline in erectile function compared with those who did not have these genotypes: 56% (9 of 16) vs. 24% (11 of 45) (p = 0.02). In addition, patients with the -509 T/T genotype had a significantly increased risk of developing late rectal bleeding compared with those who had either the C/T or C/C genotype at this position: 55% (6 of 11) vs. 26% (34 of 130) (p = 0.05). Conclusions: Possession of certain TGFB1 genotypes is associated with the development of both erectile dysfunction and late rectal bleeding in patients treated with radiotherapy for prostate cancer. Therefore, identification of patients harboring these genotypes may represent a means to predict which men are most likely to suffer from poor quality-of-life outcomes after radiotherapy for prostate cancer.

KW - Prostate cancer

KW - Radiogenomics

KW - Radiotherapy

KW - Single nucleotide polymorphisms (SNPs)

KW - Transforming growth factor β1 (TGF-β1)

UR - http://www.scopus.com/inward/record.url?scp=38849201802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=38849201802&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2007.05.023

DO - 10.1016/j.ijrobp.2007.05.023

M3 - Article

C2 - 17689884

AN - SCOPUS:38849201802

VL - 70

SP - 752

EP - 759

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 3

ER -